Hepatitis A and B vaccine (combined)
Brand names: Twinrix, Ambirix
The combined hepatitis A and B vaccine is an inactivated/recombinant vaccine that provides active immunisation against both hepatitis A and hepatitis B viruses in a single preparation, given as a multi-dose schedule.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It contains inactivated hepatitis A virus antigen and recombinant hepatitis B surface antigen which stimulate protective antibody responses to both viruses.
Prescribing in practice
- It provides no rapid protection and is unsuitable when immediate post-exposure cover is needed, and the full schedule must be completed for durable hepatitis B immunity.
- Defer in acute febrile illness and avoid in those with confirmed hypersensitivity to a vaccine component.
- It is given by intramuscular injection, normally into the deltoid, and not into the buttock or intradermally as this reduces the response.
Monitoring
Routine post-vaccination antibody testing is not generally required except in defined at-risk or occupational groups where checking the hepatitis B response is advised.
Counselling the patient
- Complete all doses in the schedule to gain full and lasting protection.
- Mild soreness at the injection site, headache or tiredness are common and short-lived.
- This vaccine is for prevention and does not treat existing infection.
Evidence & guidelines
Combined hepatitis A and B immunisation follows the schedules and indications set out in the UK immunisation guidance (Green Book).
Reference: UK Green Book; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Maddrey Discriminant Function (Alcoholic Hepatitis) · Alcoholic Liver Disease
- Lille Model (Steroid Response in Alcoholic Hepatitis) · Alcoholic Liver Disease
- FIB-4 Index · Liver Fibrosis
- Maddrey's Discriminant Function for Alcoholic Hepatitis · Hepatology
- Lille Model for Alcoholic Hepatitis · Hepatology
- AST to Platelet Ratio Index (APRI) · Hepatology
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023